Review
Atrial Fibrillation in Hypertrophic Cardiomyopathy: A Review
Laxmi Narayan Goit11,✉ , Yang Shaning2
1 Department of Cardiology, the first affiliated Hospital of Yangtze University, Jingzhou, Hubei, P.R China. 2 Department of Cardiology, clinical college of Yangtze University and the first affiliated hospital to Yangtze University, Jingzhou, Hubei, P.R China ✉ Correspondence Laxmi Narayan Goit, Department of Cardiology, the first affiliated Hospital of Yangtze University, Jingzhou, Hubei, P.R China. Email: [email protected]. Telephone number: +86-15272634003/ +9779842187350. Received: May 4, 2019; Accepted: June 26, 2019; Published online: November 7, 2019. Cite this paper: Laxmi Narayan Goit, Yang Shaning (2020) Atrial Fibrillation in Hypertrophic Cardiomyopathy: A Review. Global Journal of Life Sciences, 1(1): 2-12. https://naturescholars.com/gjls.010102. http://doi.org/10.46633/gjls.010102. Copyright© 2020 by Scholars Publishing, LLC.
Abstract
Hypertrophy cardiomyopathy (HCM) is the most common cardiomyopathy characterized by left ventricular hypertrophy and spectrum of clinical manifestation. Atrial fibrillation (AF) is the most common sustained arrhythmia in HCM patients and is primary related to left atrial dilation and remodeling. There are several clinical, electrocardiographic (ECG), and echocardiography (ECHO) feature that have been associated with development of atrial fibrillation in HCM patients, strongest predictors are left atrial size and heart failure class. AF can lead to progressive functional declines, worsening the heart failure and increased for systemic thromboembolism. The mechanism by which atrial fibrillation occurs in HCM is incompletely understood but data suggest that heart failure induced atrial fibrosis and atrial ionic remodeling are the underlying abnormalities that facilitate atrial fibrillation. The management of AF in patients with HCM includes risk factor modification and guideline directed medical therapy, rate control and rhythm control and prevention of complication such as Thromembolism. The decision whether to target a rate control or rhythm control strategy is an evolving aspect of management. As recent evidence suggest that early rhythm control strategy may result in more favorable short and long term prognosis.
Key word: Hypertrophy cardiomyopathy, Atrial fibrillation, Heart failure, Thromboembolism, Antiarrhythmic agents, and Calcium channel blockers.